Alice Abelanet

Alice Abelanet

Auto-generated profile, based on publicly available information

Alice Abelanet

Université de Limoges, CNRS, Institut de Recherche sur les Céramiques, UMR 7315, F-87000 Limoges, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2016 in Nature
Verified
Journal Article
Open access
PDF file
PTPetros A. Tyrakis
Petros A. Tyrakis
APAsís Palazón
Asís Palazón
DMDavid Macias
David Macias
KLKian. L. Lee
Kian. L. Lee
APAnthony. T. Phan
Anthony. T. Phan
RJRandall S. Johnson
Randall S. Johnson
R-2-hydroxyglutarate accumulates to millimolar levels in cancer cells with gain-of-function isocitrate dehydrogenase 1/2 mutations. These levels of R-2-hydroxyglutarate affect 2-oxoglutarate-dependent dioxygenases. Both metabolite enantiomers, R- and S-2-hydroxyglutarate, are detectible in healthy individuals, yet their physiological function remains elusive. Here we show that 2-hydroxyglutarate accumulates in mouse CD8+ T cells in response to T-cell receptor triggering, and accumulates to millimolar levels in physiological oxygen conditions through a hypoxia-inducible factor 1-alpha (HIF-1α)-dependent mechanism. S-2-hydroxyglutarate predominates over R-2-hydroxyglutarate in activated T cells, and we demonstrate alterations in markers of CD8+ T-cell differentiation in response to this metabolite. Modulation of histone and DNA demethylation, as well as HIF-1α stability, mediate these effects. S-2-hydroxyglutarate treatment greatly enhances the in vivo proliferation, persistence and anti-tumour capacity of adoptively transferred CD8+ T cells. Thus, S-2-hydroxyglutarate acts as an immunometabolite that links environmental context, through a metabolic–epigenetic axis, to immune fate and function.

30 November 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
PMPierre Mora
Pierre Mora
PHPierre-Louis Hollier
Pierre-Louis Hollier
SGSarah Guimbal
Sarah Guimbal
AAAlice Abelanet
Alice Abelanet
ADAïssata Diop
Aïssata Diop
CCCandice Chapouly
Candice Chapouly
Inflammation of the central nervous system (CNS) induces endothelial blood–brain barrier (BBB) opening as well as the formation of a tight junction barrier between reactive astrocytes at the Glia Limitans. We hypothesized that the CNS parenchyma may acquire protection from the reactive astrocytic Glia Limitans not only during neuroinflammation but also when BBB integrity is compromised in the resting state. Previous studies found that astrocyte-derived Sonic hedgehog (SHH) stabilizes the BBB during CNS inflammatory disease, while endothelial-derived desert hedgehog (DHH) is expressed at the BBB under resting conditions. Here, we investigated the effects of endothelial Dhh on the integrity of the BBB and Glia Limitans. We first characterized DHH expression within endothelial cells at the BBB, then demonstrated that DHH is down-regulated during experimental autoimmune encephalomyelitis (EAE). Using a mouse model in which endothelial Dhh is inducibly deleted, we found that endothelial Dhh both opens the BBB via the modulation of forkhead box O1 (FoxO1) transcriptional activity and induces a tight junctional barrier at the Glia Limitans. We confirmed the relevance of this glial barrier system in human multiple sclerosis active lesions. These results provide evidence for the novel concept of “chronic neuroinflammatory tolerance” in which BBB opening in the resting state is sufficient to stimulate a protective barrier at the Glia Limitans that limits the severity of subsequent neuroinflammatory disease. In summary, genetic disruption of the BBB generates endothelial signals that drive the formation under resting conditions of a secondary barrier at the Glia Limitans with protective effects against subsequent CNS inflammation. The concept of a reciprocally regulated CNS double barrier system has implications for treatment strategies in both the acute and chronic phases of multiple sclerosis pathophysiology.

29 November 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MBMarie-Lise Bats
Marie-Lise Bats
PBPauline Bougaran
Pauline Bougaran
CPClaire Peghaire
Claire Peghaire
FGFlorian Gueniot
Florian Gueniot
AAAlice Abelanet
Alice Abelanet
PDPascale Dufourcq
Pascale Dufourcq
Retinopathies remain major causes of visual impairment in diabetic patients and premature infants. Introduction of anti‐angiogenic drugs targeting vascular endothelial growth factor (VEGF) has transformed therapy for these proliferative retinopathies. However, limitations associated with anti‐VEGF medications require to unravel new pathways of vessel growth to identify potential drug targets. Here, we investigated the role of Wnt/Frizzled‐7 (Fzd7) pathway in a mouse model of oxygen‐induced retinopathy (OIR). Using transgenic mice, which enabled endothelium‐specific and time‐specific Fzd7 deletion, we demonstrated that Fzd7 controls both vaso‐obliteration and neovascular phases (NV). Deletion of Fzd7 at P12, after the ischemic phase of OIR, prevented formation of aberrant neovessels into the vitreous by suppressing proliferation of endothelial cells (EC) in tufts. Next we validated in vitro two Frd7 blocking strategies: a monoclonal antibody (mAbFzd7) against Fzd7 and a soluble Fzd7 receptor (CRD). In vivo a single intravitreal microinjection of mAbFzd7 or CRD significantly attenuated retinal neovascularization (NV) in mice with OIR. Molecular analysis revealed that Fzd7 may act through the activation of Wnt/β‐catenin and Jagged1 expression to control EC proliferation in extra‐retinal neovessels. We identified Fzd7/β‐catenin signaling as new regulator of pathological retinal NV. Fzd7 appears to be a potent pharmacological target to prevent or treat aberrant angiogenesis of ischemic retinopathies.

1 May 2022 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
SRSebastien Rubin
Sebastien Rubin
PBPauline Bougaran
Pauline Bougaran
SMSoizic Martin
Soizic Martin
AAAlice Abelanet
Alice Abelanet
VDValentin Delobel
Valentin Delobel
CDCecile Duplaa
Cecile Duplaa
Background: Genome-wide association studies have revealed robust associations of common genetic polymorphisms in an intron of the PHACTR-1 (phosphatase and actin regulator 1) gene (chr6p24), with cervical artery dissection, spontaneous coronary artery dissection, and fibromuscular dysplasia. The aim was to assess its role in the pathogenesis of cervical artery dissection or fibromuscular dysplasia. Methods: Using various tissue-specific Cre-driver mouse lines, Phactr1 was deleted either in endothelial cells using 2 tissue-specific Cre-driver (PDGFB [platelet-derived growth factor B]-CreERT2 mice and Tie2 [tyrosine kinase with immunoglobulin and EGF homology domains]-Cre) and smooth muscle cells (smooth muscle actin-CreERT2) with a third tissue-specific Cre-driver. Results: To test the efficacy of the Phactr1 deletion after cre-induction, we confirmed first, a decrease in Phactr1 transcription and Phactr1 expression in endothelial cell and smooth muscle cell isolated from Phactr1iPDGFB and Phactr1iSMA mice. Irrespective to the tissue or the duration of the deletion, mice did not spontaneously display pathological phenotype or vascular impairment: mouse survival, growth, blood pressure, large vessel morphology, or actin organization were not different in knockout mice than their comparatives littermates. Challenging vascular function and repair either by angiotensin II–induced hypertension or limb ischemia did not lead to vascular morphology or function impairment in Phactr1-deleted mice. Similarly, there were no more consequences of Phactr1 deletion during embryogenesis in endothelial cells. Conclusions: Loss of PHACTR-1 function in the cells involved in vascular physiology does not appear to induce a pathological vascular phenotype. The in vivo effect of the intronic variation described in genome-wide association studies is unlikely to involve downregulation in PHACTR-1 expression.

Verified
Journal Article
Open access
PDF file
JUJulie Usseglio
Julie Usseglio
ADAdeline Dumur
Adeline Dumur
EPEsther Pagès
Esther Pagès
ÉRÉmeline Renaudie
Émeline Renaudie
AAAlice Abélanet
Alice Abélanet
AMAmandine Magnaudeix
Amandine Magnaudeix
Incorporation of silicate ions in calcium phosphate ceramics (CPC) and modification of their multiscale architecture are two strategies for improving the vascularization of scaffolds for bone regenerative medicine. The response of endothelial cells, actors for vascularization, to the chemical and physical cues of biomaterial surfaces is little documented, although essential. We aimed to characterize in vitro the response of an endothelial cell line, C166, cultivated on the surface CPCs varying either in terms of their chemistry (pure versus silicon-doped HA) or their microstructure (dense versus microporous). Adhesion, metabolic activity, and proliferation were significantly altered on microporous ceramics, but the secretion of the pro-angiogenic VEGF-A increased from 262 to 386 pg/mL on porous compared to dense silicon-doped HA ceramics after 168 h. A tubulogenesis assay was set up directly on the ceramics. Two configurations were designed for discriminating the influence of the chemistry from that of the surface physical properties. The formation of tubule-like structures was qualitatively more frequent on dense ceramics. Microporous ceramics induced calcium depletion in the culture medium (from 2 down to 0.5 mmol/L), which is deleterious for C166. Importantly, this effect might be associated with the in vitro static cell culture. No influence of silicon doping of HA on C166 behavior was detected.

4 April 2026
Verified
Thesis
Closed access
AAAlice Abelanet
Alice Abelanet
L’insuffisance cardiaque à fraction d’éjection préservée (ICFEp) est une maladie chronique associée à une mortalité élevée. Les patients sont majoritairement des femmes âgées (>65 ans) hypertendues avec une prévalence élevée de comorbidités cardiovasculaires telles que l’obésité, le diabète de type 2, l’hypertension artérielle ou encore la fibrillation atriale. Le diagnostic de l’ICFEp est difficile à établir en raison d’un manque de critères spécifiques et il n’existe pas à ce jour de réel traitement ciblé permettant d’améliorer la qualité de vie, de réduire la mortalité ou la durée d’hospitalisation de ces patients. Malheureusement, les mécanismes moléculaires sous-jacents de cette maladie sont encore mal compris mais un nouveau paradigme a été proposé ces dernières années. Il suggère un rôle central de la dysfonction des cellules endothéliales cardiaques dans l’apparition de l’ICFEp. L'ubiquitine ligase E3 RING PDZRN3, est un médiateur de la voie Wnt non-canonique qui régule la morphogénèse vasculaire ainsi que l’intégrité des cellules endothéliales. Nos travaux ont eu pour objectif d’étudier les conséquences de l'activation de la signalisation endothéliale PDZRN3 sur la fonction cardiaque.Nous avons généré des souris transgéniques avec une surexpression spécifique de PDZRN3 dans les cellules endothéliales et inductible en post-natal (souris iEC-Pdzrn3). A partir de 3 mois, les souris iEC-Pdzrn3 présentent des paramètres hémodynamiques d’ICFEp avec une élévation significative de la pression diastolique par rapport à leurs contrôles. À 8 mois, les souris iEC-Pdzn3 ne présentent pas un phénotype cardiaque dit inflammatoire ni de signes de progression de fibrose. Cependant, en plus de signes de dysfonction diastolique, une perméabilité vasculaire accrue mise en évidence par une extravasation vasculaire d'albumine, de fibrinogène et d'immunoglobuline G associée à un œdème cardiaque ont été observés. De plus, la mise sous régime Western a exacerbé le phénotype inflammatoire et fibrotique des souris iEC-Pdzrn3 mais aussi de leurs contrôles sans aggraver le dysfonctionnement diastolique. Enfin, l'exploration cardiaque d’un modèle murin d’ICFEp basé sur les comorbidités obésité et diabète (souris Lprdb/db) a révélé une perméabilité vasculaire comparable à celle observée chez les souris iEC-Pdzrn3.Ces résultats mettent donc en évidence une relation de cause à effet entre le dysfonctionnement vasculaire et la physiopathologie de l’ICFEp.